Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

ASCO Issues Guideline on Biomarker-Based Adjuvant Breast Cancer Treatment

  • Anna Azvolinsky
February 9, 2016
  • Practice & Policy, Breast Cancer, Breast Cancer Targets

The American Society of Clinical Oncology (ASCO) has published a guideline on biomarker use to guide decisions for adjuvant systemic treatment for women with early-stage, invasive breast cancer. The guideline was published in the Journal of Clinical Oncology.

Besides the use of assays to identify women with estrogen receptor (ER)- and/or progesterone receptor (PR)-positive or human epidermal growth factor receptor 2 (HER2)-positive diseases, the authors found satisfactory clinical trial data and prospective-retrospective studies to recommend the use of six biomarker assays in specific patient subgroups.

The guideline panel found sufficient evidence to include Oncotype DX, EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 assays.

Daniel F. Hayes, MD, clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center, and colleagues identified one randomized clinical trial and 18 prospective-retrospective studies that evaluated the clinical utility of specific biomarkers for use in guiding adjuvant treatment decisions in breast cancer.

“A biomarker-based test is judged to have clinical utility if use of the test is associated with a favorable balance of benefits to harms compared with treatment of the patient in the absence of the biomarker test result,” the authors wrote.

The authors of the guideline recommend that clinicians educate patients, family members, and/or caregivers on the results of pathology tests and how the results are used to tailor treatment decisions based on the biology of the tumor.

Select Strong Recommendations:

• If a patient has ER/PR-positive, HER2-negative (node-negative) breast cancer, the clinician may use the 21-gene recurrence score (Oncotype DX) to guide decisions on adjuvant systemic chemotherapy.

• If a patient has HER2-positive breast cancer or triple-negative breast cancer, the clinician should not use the 21-gene recurrence score (Oncotype DX) to guide decisions on adjuvant systemic therapy.

• If a patient has HER2-positive breast cancer or triple-negative breast cancer, the clinician should not use the 12-gene risk score (EndoPredict) to guide decisions on adjuvant systemic therapy.

• If a patient has triple-negative breast cancer, the clinician should not use the 70-gene assay (MammaPrint) to guide decisions on adjuvant systemic therapy.

• If a patient has ER/PR-positive, HER2-negative (node-negative) breast cancer, the clinician may use the PAM50 risk-of-recurrence score (Prosigna Breast Cancer Prognostic Gene Signature Assay) in conjunction with other clinicopathologic variables to guide decisions on adjuvant systemic therapy.

­• If a patient has HER2-positive or triple-negative breast cancer, the clinician should not use the PAM50 risk-of-recurrence score to guide decisions on adjuvant systemic therapy.

• If a patient has ER/PR-positive, HER2-negative (node-positive) breast cancer, HER2-positive breast cancer, or triple-negative breast cancer, the clinician should not use the Breast Cancer Index to guide decisions on adjuvant systemic therapy.

ASCO has also recently published a separate guideline to guide decisions on systemic therapy for women with metastatic breast cancer.

Related Articles

  • FDA Approves Abbreviated New Drug Applications for Everolimus Generic Drug
  • Nancy Davidson, MD, Discusses Advancements in Breast Cancer
  • FDA Approves FoundationOne CDx as Companion Diagnostic for Alpelisib
  • Chemical Straighteners and Permanent Hair Dyes May Increase Breast Cancer Risk
  • Patrick I. Borgen, MD, Discusses Upcoming Breast Cancer Conferences

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".